ATHE Alterity Therapeutics Limited

16

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

AU | NASDAQ | Stock

Price
$3.95
Increased by +0.77%
Dollar Volume
114.21 K
ADR%
6.47
Market Cap.
17.22 M
Shares Float
3.45 M
Shares Outstanding
4.01 M
Beta
0.90
Price / Earnings
-16.46
BPR
17.83
20D Range
3.21 4.45
50D Range
2.90 4.45
200D Range
2.90 8.50
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 20 941.66 K
Increased by +598.23%
 -4.28 M
Decreased by -156.85%
Decreased by -454.61%
Increased by +63.21%
Jun 30, 20 -927.59 K
Decreased by -882.24%
 -3.91 M
Decreased by -0.15%
Increased by +421.34%
Increased by +112.80%
Jun 30, 08 119.16 K
Decreased by -37.43%
 -1.75 M
Increased by +40.27%
Decreased by -1.47 K%
Increased by +4.53%
Dec 31, 07 126.96 K
Decreased by -41.58%
 -5.05 M
Decreased by -97.53%
Decreased by -3.98 K%
Decreased by -238.10%
Jun 30, 07 134.87 K
Decreased by -78.29%
 -1.67 M
Increased by +80.99%
Decreased by -1.24 K%
Increased by +12.47%
Dec 31, 06 118.58 K
Decreased by -82.69%
 -3.90 M
Decreased by -9.24%
Decreased by -3.29 K%
Decreased by -531.11%
Jun 30, 06 190.45 K
Decreased by -68.28%
 -2.93 M
Decreased by -0.18%
Decreased by -1.54 K%
Decreased by -215.85%
Dec 31, 05 217.31 K
Decreased by -61.31%
 -2.56 M
Decreased by -26.58%
Decreased by -1.18 K%
Decreased by -227.18%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.